Consensus Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
4.85 ^USD	-6.37%		-14.16%	-14.16%

09/05	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/05	Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board	CI

Evolution of the average Target Price on Monte Rosa Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b444090af763da18d2061cf.lpNzU3J-RE__Ek3DMyNQjJ7lSAQj2kR8kfEHQ7zgyFs.--JLFxwOPRe8VSm5em0T4empEk5W9y8s-bJdLt2Y8C2uxCxhLUYKCb1FBA~308914a47fc4d081fa542b3cdafbc3eb

Analyst Recommendations on Monte Rosa Therapeutics, Inc.

UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating	29/04	MT
Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target	15/02	MT
Credit Suisse Trims Monte Rosa Therapeutics' Price Target to $11 From $12, Keeps Neutral Rating	17/23/17	MT
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18	03/23/03	MT
UBS Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $22 Price Target	13/22/13	MT
Jefferies Starts Monte Rosa Therapeutics at Buy With $20 Price Target	15/22/15	MT
Piper Sandler Adjusts Price Target on Monte Rosa Therapeutics to $21 From $40, Reiterates Overweight Rating	12/22/12	MT
Credit Suisse Initiates Monte Rosa Therapeutics at Neutral, $19 Price Target	28/22/28	MT
Berenberg Bank Adjusts Monte Rosa Therapeutics' Price Target to $28 From $32, Maintains Buy Rating	30/22/30	MT
Wells Fargo Starts Monte Rosa Therapeutics at Equalweight With $19 Price Target	10/22/10	MT
Guggenheim Adjusts Price Target for Monte Rosa Therapeutics to $35 From $40, Maintains Buy Rating	03/22/03	MT
Berenberg Bank Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $32 Price Target	17/21/17	MT
MONTE ROSA THERAPEUTICS : SVB Leerink Starts Monte Rosa Therapeutics at Market Perform with $20 Price Target	14/21/14	MT
MONTE ROSA THERAPEUTICS : JPMorgan Initiates Monte Rosa Therapeutics at Overweight Rating With $38 Price Target	19/21/19	MT
MONTE ROSA THERAPEUTICS : Cowen Initiates Coverage on Monte Rosa Therapeutics With Outperform Rating	19/21/19	MT
MONTE ROSA THERAPEUTICS : Piper Sandler Starts Monte Rosa Therapeutics at Overweight With $40 Price Target	19/21/19	MT
MONTE ROSA THERAPEUTICS : Guggenheim Starts Monte Rosa Therapeutics at Buy With $30 Price Target	19/21/19	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.85 USD

Average target price

15.43 USD

Spread / Average Target

+218.11%

High Price Target

20 USD

Spread / Highest target

+312.37%

Low Price Target

9 USD

Spread / Lowest Target

+85.57%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Monte Rosa Therapeutics, Inc.

UBS
Wedbush
Credit Suisse
Wells Fargo Securities
Jefferies & Co.
Piper Sandler
Berenberg Bank
Guggenheim
SVB Leerink
Cowen
JPMorgan Chase

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar